<DOC>
	<DOCNO>NCT02207257</DOCNO>
	<brief_summary>This study evaluate establishment anticoagulation ( `` re-anticoagulation '' ) subject edoxaban follow reversal PER977 identify dose regimen PER977 reverse effect edoxaban 21 hour .</brief_summary>
	<brief_title>Study PER977 Administered Subjects With Steady State Edoxaban Dosing Re-anticoagulation With Edoxaban</brief_title>
	<detailed_description>This randomize , single-blind , sequential group , ascend PER977 reversal dose study healthyvolunteers . Subjects randomize 4:1 ratio receive either PER977 placebo . All subject receive single dose edoxaban 60 mg Days 1-4 . On Days 3 4 , study drug adminsitered 3 hour follow edoxaban . Begining Cohort 2 , study drug administer subject minimum increase whole blood clotting time &gt; 25 % baseline . Pharmacokinetic assessment PER977 ti metabolite , edoxaban metabolite perform . Pharmacodynamic assessment WBCT Point Care prothrombin time perform . Safety assess throughout study .</detailed_description>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>1 . Adults age 18 65 year , inclusive 2 . Laboratory value clinically significant 3 . No clinically significant finding 12lead electrocardiogram 4 . Body mass index ( BMI ) 18 ≤ 32 kg/m2 , inclusive 5 . Male subject agree use appropriate contraception . 6 . Female subject may postmenopausal , childbearing potential , must negative serum pregnancy test prior enrollment , must agree use two form acceptable contraception duration study minimum one complete menstrual cycle 28 day follow discharge study . 7 . Subjects must sign informed consent 1 . History current evidence clinically significant disease , liver function test great upper limit normal ( presence Gilbert 's syndrome acceptable ) , QTcF &gt; normal ( 440±10 msec male 460±10 msec female ) . 2 . History unexplained syncope 3 . History major bleeding , trauma , surgical procedure type , vaginal delivery within six month prior screen 4 . History peptic ulcer , gastrointestinal bleeding , include mouth , within six month prior screen 5 . History minor bleeding episode epistaxis , rectal hemorrhoidal bleed gingival bleeding within 1 month prior screen 6 . Personal family history clot disorder abnormality , excessive bleeding , thrombovascular disease hematologic disorder involve platelet clot abnormality condition require treatment transfusion , history heparininduced thrombocytopenia 7 . Females history dysfunctional uterine bleeding , menorrhagia , metrorrhagia polymenorrhea 8 . Pregnant breastfeed 9 . Males history hormone therapy within 3 month prior screen 10 . Administration blood product anticoagulant within 3 month prior study entry non steroidal antiinflammatory drug cyclooxygenase inhibitor within 2 week prior screen 11 . Taking type chronic medication within 4 week prior study entry ( use hormonal contraceptive acceptable ) 12 . Positive serologic test HIV , HCVAb , HBsAG 13 . Donation blood blood product within 56 day prior screen 14 . Smokers use tobacco and/or nicotine containing product within 3 month prior dose determine subject 's verbal history 15 . Participation study investigational compound device within 30 day prior sign inform consent 16 . History participation prior study PER977 edoxaban 17 . Active drug alcohol dependence within prior 12 month condition , opinion Investigator , would interfere adherence study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>PER977</keyword>
	<keyword>anticoagulation reversal</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>edoxaban</keyword>
	<keyword>whole blood clotting time</keyword>
	<keyword>D-dimer</keyword>
	<keyword>prothrombin fragment 1 2</keyword>
	<keyword>tissue factor pathway inhibitor</keyword>
	<keyword>prothrombin time</keyword>
</DOC>